Revex Related Published Studies
Well-designed clinical trials related to Revex (Nalmefene)
Nalmefene: a review of its use in the treatment of alcohol dependence. [2013]
A randomized, double-blind, vehicle-controlled crossover study to determine the anti-pruritic efficacy, safety and local dermal tolerability of a topical formulation (srd174 cream) of the long-acting opiod antagonist nalmefene in subjects with atopic dermatitis. [2011.08]
A randomized, double-blind, vehicle-controlled crossover study to determine the
anti-pruritic efficacy, safety and local dermal tolerability of a topical
formulation (srd174 cream) of the long-acting opiod antagonist nalmefene in
subjects with atopic dermatitis. [2011]
Nalmefene in the treatment of pathological gambling: multicentre, double-blind,
placebo-controlled study. [2010]
Effects of opioid receptor gene variation on targeted nalmefene treatment in heavy drinkers. [2008.07]
Effects of Opioid Receptor Gene Variation on Targeted Nalmefene Treatment in Heavy Drinkers. [2008.06.03]
Targeted nalmefene with simple medical management in the treatment of heavy drinkers: a randomized double-blind placebo-controlled multicenter study. [2007.07]
Multicenter investigation of the opioid antagonist nalmefene in the treatment of pathological gambling. [2006.02]
Well-designed clinical trials possibly related to Revex (Nalmefene)
The Gambling Symptom Assessment Scale (G-SAS): a reliability and validity study. [2009.03.31]
Predicting response to opiate antagonists and placebo in the treatment of pathological gambling. [2008.11]
Other research related to Revex (Nalmefene)
Effect of nalmefene 20 and 80 mg on the corrected QT interval and T-wave morphology: a randomized, double-blind, parallel-group, placebo- and moxifloxacin-controlled, single-centre study. [2011.11.01]
Effect of Nalmefene 20 and 80 mg on the Corrected QT Interval and T-Wave Morphology: A Randomized, Double-Blind, Parallel-Group, Placebo- and Moxifloxacin-Controlled, Single-Centre Study. [2011.09.23]
Nalmefene for treatment of alcohol dependence. [2010.11]
Nalmefene in the treatment of pathological gambling: multicentre, double-blind, placebo-controlled study. [2010.10]
[Clinical observation of the effect of nalmefene in treatment of septic shock] [2010.06]
In vivo characterization of the opioid antagonist nalmefene in mice. [2010.04.10]
[Clinical observation of the effect of nalmefene in treatment of septic shock]. [Article in Chinese] [2010]
[Pharmacokinetics of nalmefene after a single or multiple intravenous doses in Chinese healthy volunteers.] [2008.10]
Targeted Nalmefene With Simple Medical Management in the Treatment of Heavy Drinkers: A Randomized Double-Blind Placebo-Controlled Multicenter Study. [2007.04.19]
Prolonged central mu-opioid receptor occupancy after single and repeated nalmefene dosing. [2005.12]
Determination of nalmefene by high-performance liquid chromatography-electrospray ionization-tandem mass spectrometry. [2005.04]
Stimulation of the hypothalamic-pituitary-adrenal axis with the opioid antagonist nalmefene. [2005]
Other possibly related research studies
Opioid antagonists for alcohol dependence. [2005.01.25]
Plasma met-enkephalin, beta-endorphin and leu-enkephalin levels in human hepatic encephalopathy. [2007.03]
Emerging pharmacologic options for treating postoperative ileus. [2007.10.15]
Pharmacological evidence for a motivational role of kappa-opioid systems in ethanol dependence. [2008.02]
Opioid antagonists for pharmacological treatment of alcohol dependence - a critical review. [2008.11]
Opioid antagonists under heavy sedation or anaesthesia for opioid withdrawal. [2010.01.20]
Opioid-like compound exerts anti-fibrotic activity via decreased hepatic stellate cell activation and inflammation. [2011.04.15]
Opioid antagonists for alcohol dependence. [2010.12.08]
Human exposures to immobilising agents: results of an online survey. [2010.08.28]
Emerging drugs to treat alcoholism. [2010.12]
Antipruritic treatment with systemic mu-opioid receptor antagonists: a review. [2010.10]
Opioid antagonists under heavy sedation or anaesthesia for opioid withdrawal. [2010]
|